Christopher Fotsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher Fotsch has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Clarence Hale
Departments of Chemical Research and Development, Metabolic Disorders, and Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, and Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080
3 shared publicationsQingyian Liu
Departments of Chemical Research and Development, Metabolic Disorders, and Pharmacokinetics and Drug Metabolism, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, and Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080
3 shared publications- David J. St. Jean
Amgen Inc Thousand Oaks Calif
2 shared publications Feng-Yin Hsieh
Amgen Inc., Department of Pharmacokinetics and Drug Metabolism, One Amgen Center Drive, Thousand Oaks, CA 91360, USA
2 shared publicationsJiandong Zhang
2 shared publicationsMichael Croghan
2 shared publications
Latest Publications
- Open Access
- 7 May 2024
- Published by Elsevier in SLAS Discovery
- Vol. 29 (4) , 100159
Creating a more strategic small molecule biophysical hit characterization workflow
- 7 May 2024
- Published by Elsevier in SLAS Discovery
- Vol. 29 (4) , 100159
Open AccessCreating a more strategic small molecule biophysical hit characterization workflow
- 19 November 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (24) , 7953-7967
Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR). To try and mitigate the PXR activity, we prepared analogues of our lead series that contained polar groups on the right-hand side of the thiazolone. Several analogues containing amides or alcohols appended to the C-5 position of the thiazolone showed a significant reduction in PXR activity. Through these structure−activity efforts, a compound containing a tert-alcohol group off the C-5 position, analogue (S)-33a, was found to have an 11β-HSD1 Ki = 35 nM and negligible PXR activity. Compound (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11β-HSD1 activity after being orally administered.
- 19 November 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (24) , 7953-7967
Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR). To try and mitigate the PXR activity, we prepared analogues of our lead series that contained polar groups on the right-hand side of the thiazolone. Several analogues containing amides or alcohols appended to the C-5 position of the thiazolone showed a significant reduction in PXR activity. Through these structure−activity efforts, a compound containing a tert-alcohol group off the C-5 position, analogue (S)-33a, was found to have an 11β-HSD1 Ki = 35 nM and negligible PXR activity. Compound (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11β-HSD1 activity after being orally administered.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 8 (17) , 1508-1523
Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme that converts cortisone to cortisol. A growing body of evidence suggests that selective inhibition of 11β-HSD1 could potentially treat the metabolic syndrome. This review provides an overview of compounds reported to have in vivo inhibitory activity against this enzyme. A major focus of this review is Amgens 11β-HSD1 program which includes a variety of in vivo data for a lead compound from our thiazolone class of inhibitors. Finally, an update on the current known clinical data is discussed.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 8 (17) , 1508-1523
Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme that converts cortisone to cortisol. A growing body of evidence suggests that selective inhibition of 11β-HSD1 could potentially treat the metabolic syndrome. This review provides an overview of compounds reported to have in vivo inhibitory activity against this enzyme. A major focus of this review is Amgens 11β-HSD1 program which includes a variety of in vivo data for a lead compound from our thiazolone class of inhibitors. Finally, an update on the current known clinical data is discussed.
- 15 April 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (8) , 2071-2075
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core
- 15 April 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (8) , 2071-2075
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core
- 15 March 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (6) , 1623-1627
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides
- 15 March 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (6) , 1623-1627
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides
- 21 July 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (14) , 2337-2340
Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-dPhe-Arg-Trp-Lys]-NH2
- 21 July 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (14) , 2337-2340
Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-dPhe-Arg-Trp-Lys]-NH2